Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8653275

[Systemic enzyme therapy].

A Libický·K Nouza
View original source ↗Export metadata ↓

Abstract

The paper summarizes the hitherto knowledge concerning the absorption of perorally administered enzymes in the digestive tract. After the transport through the intestinal wall the enzymes are protected against immunity recognition and they reach the affected regions via blood and lymphatic routes. A survey of enzymes taken into consideration and the essence of their action are presented. In the final part, the fields are summed up in which systemic enzymotherapy proves useful.

Explore related subjects

Enzyme TherapyEnzymesHumansMacromolecular SubstancesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Libický, K Nouza. 1996. [Systemic enzyme therapy].. https://pubmed.ncbi.nlm.nih.gov/8653275/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Saccadic analysis for early identification of neurological involvement in Gaucher disease.

The early identification of a neurological involvement in Gaucher's Disease (GD) is essential for a correct dosage of the enzymatic therapy. The saccadic eye movement characteristics of 15 patients affected by the non-neurological GD form show normal peak velocity values and some slight alterations of the velocity profiles present in more than 70% of the recorded eye movements in four cases; two of them later developed epilepsy. This fact supports the hypothesis that the presence of alterations in the velocity profile of the most part of saccadic movements is an index of initial neurological involvement. Further evaluations are necessary in order to understand if an increase of therapy dose should be used in all the subjects presenting such saccadic alterations.

Enzyme Therapy↗
PubMed2004

Enzyme replacement and enhancement therapies for lysosomal diseases.

Although first suggested by de Duve in 1964, enzyme replacement therapy (ERT) for lysosomal storage diseases did not become a reality until the early 1990s when its safety and effectiveness were demonstrated in type 1 Gaucher disease. Today, ERT is a reality for Gaucher disease, Fabry disease and mucopolysaccharidosis type I (MPS I), and clinical trials with recombinant human enzymes are ongoing in Pompe disease, MPS II and MPS VI, and are about to begin in Neimann-Pick B disease. In addition to ERT, enzyme enhancement therapy (EET) offers a novel therapeutic strategy to increase the residual function of mutant proteins. EET employs small molecules as 'pharmacological chaperones' to rescue misfolded and/or unstable mutant enzymes or proteins that have residual function. EET also offers the possibility of treating neurodegenerative lysosomal disorders since these small therapeutic molecules may cross the blood-brain barrier. The current status of ERT and the prospects for EET for lysosomal storage diseases are reviewed.

Enzyme Therapy↗